Mesoblast (MESO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked analysts ...

FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:MESO; ASX:MSB), ...

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapyNEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited ...

Mesoblast’s Revascor gets US FDA’s regenerative medicine advanced therapy designation in children with congenital heart disease: New York Friday, December 6, 2024, 18:00 Hrs [ ...

Mesoblast Limited announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure, which re ...

Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced ...

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE ...

This identifies the target HFrEF population that is responsive to REVASCOR therapy. DREAM-HF’s lead investigator, Dr. Emerson C. Perin, MD, PhD, FACC, Medical Director at The Texas Heart ...

Mesoblast Chief Executive Silviu Itescu said: “We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long ...

Highlights,Mesoblast has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its ...

Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy designation to its Revascor (rexlemestrocel-L) drug for children ...